On the benefit of whey-cultured Lactobacillus casei in murine colitis

Journal of Physiology and Pharmacology

Volumn 62, Issue 3, 2011, Pages 341-346

  Ghasemi Niri, S F ^a,b   Abdolghaffari, A H ^c   Fallah Benakohal, S ^b   Hosseinpour Feizi, M ^b   Mahdaviani, P ^a   Jamalifar, H ^b   Baeeri, M ^a   Dehghan, G ^b   Abdollahi, M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TABRIZ   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Colitis; Colonic myeloperoxidase; Inflammatory bowel disease; Lactobacillus casei; Lipid peroxidation; Probiotics; Tumor necrosis factor

Indexed keywords

DEXAMETHASONE; MYELOPEROXIDASE; PLACEBO; PROBIOTIC AGENT; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM CULTURE; CHEMICAL ANALYSIS; COLITIS; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; HISTOLOGY; LACTOBACILLUS CASEI; LIPID PEROXIDATION; MALE; NONHUMAN; PROPHYLAXIS; RAT; SCORING SYSTEM; THERAPY EFFECT; TISSUE HOMOGENATE; TREATMENT DURATION; WHEY;

ADMINISTRATION, RECTAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; COLON; DEXAMETHASONE; DISEASE MODELS, ANIMAL; ETHANOL; LACTOBACILLUS CASEI; LIPID PEROXIDATION; MALE; MICE; MILK PROTEINS; PEROXIDASE; PROBIOTICS; RATS; RATS, WISTAR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80355123805     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 2010; 6: 339-346.
2. Salari P, Abdollahi M. Controversial effects of non-steroidal anti-inflammatory drugs on bone: a review. Inflamm Allergy Drug Targets 2009; 8: 169-175.
3. Hosseini-Tabatabaei A, Abdollahi M. Potassium channel openers and improvement of toxic stress: Do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Targets 2008; 7: 129-135.
4. Hanauer SB, Sparrow M. Therapy of ulcerative colitis. Curr Opin Gastroenterol 2004; 20: 345-350.
5. Seksik P, Dray X, Sokol H, Marteau P. Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? Mol Nutr Food Res 2008; 52: 906-912.
6. Andus T, Gross V. Etiology and pathophysiology of inflammatory bowel disease-environmental factors. Hepatogastroenterology 2000; 47: 29-43.
7. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007; 52: 2015-2021.
8. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a metaanalysis of controlled clinical trials. Dig Dis Sci 2008; 53: 1278-1284.
9. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Ameta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008; 4: 185-190.
10. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53: 2524-2531.
11. Ebrahimi F, Esmaily H, Baeeri M, Mohammadirad A, Fallah S, Abdollahi M. Molecular evidences on the benefit of Nacetylcysteine in experimental colitis. Cent Eur J Biol 2008; 3: 135-132.
12. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci 2009; 54: 471-480.
13. Kaur IP, Chopra K, Saini A. Probiotics: potential pharmaceutical applications. Eur J Pharm Sci 2002; 15: 1-9.
14. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998; 39: 237-238.
15. Isaacs K, Herfarth H. Role of probiotic therapy in IBD. Inflamm Bowel Dis 2008; 14: 1597-1605.
16. Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010; 16: 4504-4514.
17. Dieleman LA, Goerres MS, Arends A, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003; 52: 370-376.
18. Matsumoto S, Hara T, Hori T, et al. Probiotic Lactobacillusinduced improvement in murine chroni inflammatory bowel disease is associated with the down-regulation of proinflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005; 140: 417-426.
19. Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002; 51: 659-664.
20. Chung YW, Choi JH, Oh TY, Eun CS, Han DS. Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice. Clin Exp Immunol 2008; 151: 182-189.
21. Llopis M, Antolin M, Guarner F, Salas A, Malagelada JR. Mucosal colonization with Lactobacillus casei mitigates barrier injury induced by exposure totrinitronbenzenesulphonic acid. Gut 2005; 54: 955-959.
22. Cherbut C, Michel C, Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis inrats. J Nutr 2003; 133: 21-27.
23. Abdollahi M, Dehpour AR, Baharnouri G. Alteration by rubidium of rat submandibular secretion of protein and Nacetyl-D-glucosaminidase. Toxic Subst Mech 1998; 17: 121-131.
24. Abdolghaffari AH, Baghaei A, Moayer F, et al. On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. Hum Exp Toxicol 2010; 29: 287-295.
25. Nakhai LA, Mohammadirad A, Yasa N, et al. Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease. Evid Based Complement Alternat Med 2007; 4: 43-50.
26. Ghazanfari G, Minaie B, Yasa N, et al. Biochemical and histopathological evidences for beneficial effects of saturejakhuzestanicajamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol Mech Methods 2006; 16: 365-372.
27. Tien MT, Girardin SE, Regnault B, et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol 2006; 176: 1228-1237.
28. Flynn S, van Sinderen D, Thornton GM, Holo H, Nes IF, Collins JK. Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118. Microbiology 2002; 148: 973-984.
29. Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004; 50: 81-92.
30. Konturek PC, Sliwowski Z, Koziel J, et al. Probiotic bacteria Escherichia coli strain Nissle 1917 attenuates acute gastric lesions induced by stress. J Physiol Pharmacol 2009; 60: 41-48.
31. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a metaanalysis of randomized, controlled trials. Dis Colon Rectum 2008; 51: 1775-1780.
32. Shen C, De Hertogh G, Bullens DM, et al. Remissioninducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflamm Bowel Dis 2007; 13: 308-316.
33. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-a in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 2007; 13: 13-18.
34. Schultz M, Linde HJ, Lehn N, et al. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res 2003; 70: 165-173.
35. Mustafa A, El-Medany A, Hagar HH, El-Medany G. Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. Pharmacol Res 2006; 53: 324-330.
36. Chung YW, Choi JH, Oh TY, Eun CS, Han DS. Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4mutant mice. Clin Exp Immunol 2008; 151: 182-189.
37. Ohashi Y, Ushida K. Health-beneficial effects of probiotics: its mode of action. Anim Sci J 2009; 80: 361-371.
38. Galdeano CM, de Leblanc Ade M, Carmuega E, Weill R, Perdigon G. Mechanisms involved in the immunostimulation by probiotic fermented milk. J Dairy Res 2009; 76: 446-454.
39. Hegazy SK, El-Bedewy MM. Effect of probiotics on proinflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010; 16: 4145-4151.
40. Esmaily H, Hosseini-Tabatabaei A, Rahimian R, et al. On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells. Cent Eur J Biol 2009; 4: 204-213.
41. Bay BH, Lee YK, Tan BK, Ling EA. Lipid peroxidative stress and antioxidative enzymes in brains of milksupplemented rats. Neurosci Lett 1999; 277: 127-130.
42. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999; 276: 941-950.
43. Cadieux PA, Burton J, Devillard E, Reid G. Lactobacillus by-products inhibit the growth and virulence of uropathogenic Escherichia coli. J Physiol Pharmacol 2009; 60: 13-18.
44. Petrunov B, Marinova S, Markova R, et al. Cellular and humoral systemic and mucosal immune responses stimulated in volunteers by an oral polybacterialimmunomodulator "Dentavax". Int Immunopharmacol 2006; 6: 1181-1193.
45. Lam EK, Tai EK, Koo MW, et al. Enhancement of gastric mucosal integrity by Lactobacillus rhamnosus GG. Life Sci 2007; 80: 2128-2136.
46. Saunders DR, Sillery J. Effect of lactate and H+ on structure and function of rat intestine. Dig Dis Sci 1982; 27: 33-41.
47. Ichikawa H, Sakata T. Effect of L-lactic acid, short-chain fatty acids, and pH incecalinfusate on morphometric and cell kinetic parameters of rat cecum. Dig Dis Sci 1997; 42: 1598-1610.
48. Lupton JR, Coder DM, Jacobs LR. Influence of luminal pH on rat large bowel epithelial cell cycle. Am J Physiol 1985; 249: 382-388.
49. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000; 289: 1560-1563.
50. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Ameta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006; 28: 1983-1988.
51. Strus M, Janczyk A, Gonet-Surowka A, et al. Effect of hydrogen peroxide of bacterial origin on apoptosis and necrosis of gut mucosa epithelial cells as a possible pathomechanism of inflammatory bowel disease and cancer. J Physiol Pharmacol 2009; 60: 55-60.